SG11202007877SA - Expression of human foxp3 in gene edited t cells - Google Patents
Expression of human foxp3 in gene edited t cellsInfo
- Publication number
- SG11202007877SA SG11202007877SA SG11202007877SA SG11202007877SA SG11202007877SA SG 11202007877S A SG11202007877S A SG 11202007877SA SG 11202007877S A SG11202007877S A SG 11202007877SA SG 11202007877S A SG11202007877S A SG 11202007877SA SG 11202007877S A SG11202007877S A SG 11202007877SA
- Authority
- SG
- Singapore
- Prior art keywords
- expression
- cells
- gene edited
- human foxp3
- foxp3
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862663561P | 2018-04-27 | 2018-04-27 | |
US201862773414P | 2018-11-30 | 2018-11-30 | |
PCT/US2019/029159 WO2019210078A1 (fr) | 2018-04-27 | 2019-04-25 | Expression de foxp3 humain dans des lymphocytes t à édition génique |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202007877SA true SG11202007877SA (en) | 2020-09-29 |
Family
ID=68295504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202007877SA SG11202007877SA (en) | 2018-04-27 | 2019-04-25 | Expression of human foxp3 in gene edited t cells |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210253652A1 (fr) |
EP (1) | EP3784689A4 (fr) |
JP (1) | JP2021521849A (fr) |
KR (1) | KR20210005146A (fr) |
CN (1) | CN112041334A (fr) |
AU (1) | AU2019257708A1 (fr) |
CA (1) | CA3091491A1 (fr) |
IL (1) | IL277036A (fr) |
SG (1) | SG11202007877SA (fr) |
WO (1) | WO2019210078A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110139675B (zh) * | 2016-10-31 | 2023-09-29 | 西雅图儿童医院(Dba西雅图儿童研究所) | 用具有工程化稳定的内源性foxp3基因表达的cd4t细胞治疗自身免疫疾病的方法 |
CA3091688A1 (fr) | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Expression de foxp3 dans des cellules cd34+ editees |
US20200368279A1 (en) | 2019-05-21 | 2020-11-26 | Sangamo Therapeutics, Inc. | Controlled Transgene Expression in Regulatory T Cells |
US20230081343A1 (en) * | 2020-02-13 | 2023-03-16 | The Board Of Trustees Of The Leland Stanford Junior University | Crispr-based foxp3 gene engineered t cells and hematopoietic stem cell precursors to treat ipex syndrome patients |
WO2023122099A2 (fr) * | 2021-12-21 | 2023-06-29 | The Board Of Trustees Of The Leland Stanford Junior University | Édition de gènes basée sur crispr pour préserver l'épissage et l'expression d'isoformes de foxp3 1 et 2 |
CN115305237B (zh) * | 2022-07-08 | 2023-07-14 | 中南大学 | 一种优化的调节性t细胞的扩增及规模化生产的方法 |
WO2024127369A1 (fr) * | 2022-12-16 | 2024-06-20 | LifeEDIT Therapeutics, Inc. | Arn guides ciblant un gène foxp3 et procédés d'utilisation |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110123502A1 (en) * | 2007-02-21 | 2011-05-26 | Barry Simon C | Method for obtaining treg-cells |
ES2883131T3 (es) * | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
CA2973884A1 (fr) * | 2015-01-30 | 2016-08-04 | The Regents Of The University Of California | Livraison de proteines dans des cellules hematopoietiques primaires |
US10968426B2 (en) * | 2015-05-08 | 2021-04-06 | President And Fellows Of Harvard College | Universal donor stem cells and related methods |
CA3034094A1 (fr) * | 2016-08-16 | 2018-02-22 | Bluebird Bio, Inc. | Variants d'endonuclease de homing du recepteur alpha de l'il-10, compositions et methodes d'utilisation associees |
WO2018073391A1 (fr) * | 2016-10-19 | 2018-04-26 | Cellectis | Insertion de gènes cibles pour immunothérapie cellulaire améliorée |
AU2017347848A1 (en) * | 2016-10-27 | 2019-05-23 | Intima Bioscience, Inc. | Viral methods of making genetically modified cells |
CN110139675B (zh) | 2016-10-31 | 2023-09-29 | 西雅图儿童医院(Dba西雅图儿童研究所) | 用具有工程化稳定的内源性foxp3基因表达的cd4t细胞治疗自身免疫疾病的方法 |
WO2018205926A1 (fr) * | 2017-05-08 | 2018-11-15 | 中国科学院动物研究所 | Lymphocyte t modifié, procédé de préparation de ce dernier et ses utilisations |
CA3091688A1 (fr) | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Expression de foxp3 dans des cellules cd34+ editees |
-
2019
- 2019-04-25 CN CN201980028523.8A patent/CN112041334A/zh active Pending
- 2019-04-25 CA CA3091491A patent/CA3091491A1/fr active Pending
- 2019-04-25 AU AU2019257708A patent/AU2019257708A1/en active Pending
- 2019-04-25 JP JP2020560338A patent/JP2021521849A/ja active Pending
- 2019-04-25 US US16/981,213 patent/US20210253652A1/en active Pending
- 2019-04-25 EP EP19792759.3A patent/EP3784689A4/fr active Pending
- 2019-04-25 KR KR1020207033790A patent/KR20210005146A/ko active Search and Examination
- 2019-04-25 SG SG11202007877SA patent/SG11202007877SA/en unknown
- 2019-04-25 WO PCT/US2019/029159 patent/WO2019210078A1/fr active Application Filing
-
2020
- 2020-08-31 IL IL277036A patent/IL277036A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3784689A4 (fr) | 2022-01-19 |
WO2019210078A1 (fr) | 2019-10-31 |
AU2019257708A1 (en) | 2020-09-03 |
CN112041334A (zh) | 2020-12-04 |
EP3784689A1 (fr) | 2021-03-03 |
JP2021521849A (ja) | 2021-08-30 |
CA3091491A1 (fr) | 2019-10-31 |
US20210253652A1 (en) | 2021-08-19 |
IL277036A (en) | 2020-10-29 |
KR20210005146A (ko) | 2021-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL277036A (en) | Expression of human FOXP3 in genetically engineered T cells | |
IL277039A (en) | Expression of FOXP3 in edited CD34 cells | |
EP3728596A4 (fr) | Construction d'acide nucléique permettant l'expression d'un gène in vitro et in vivo | |
HK1250481A1 (zh) | 經過修飾的t細胞及其製備和使用方法 | |
EP3443085A4 (fr) | Édition du génome de cellules souches neurales humaines à l'aide de nucléases | |
HK1249117A1 (zh) | 優化的人類凝血因子viii基因表達盒及其用途 | |
EP3423564A4 (fr) | Cellules microgliales dérivées de cellules souches pluripotentes et méthodes de préparation et d'utilisation de ces dernières | |
IL247756B (en) | Preparations and methods for increasing gene expression in frogs | |
EP3568467A4 (fr) | Lymphocytes t modifiés et leurs procédés d'utilisation | |
AU363796S (en) | Nail care instruments | |
EP3686275A4 (fr) | Lymphocyte t d'édition de gènes et utilisation associée | |
IL237530A0 (en) | Gene and protein expression characteristics of adherent stromal cells grown in 3D | |
EP3630978A4 (fr) | Cassettes optimisées d'expression génétique du facteur ix de coagulation humain et leur utilisation | |
EP3100468A4 (fr) | Transfert d'énergie et de données dans des prothèses auditives | |
IL280240A (en) | T-cells containing nef and methods for their production | |
GB201907690D0 (en) | Electrochemical cells and methods of making and using thereof | |
IL275037A (en) | CRISPR-CAS9-modified CD34+ human hematopoietic stem and progenitor cells and uses thereof | |
IL290297A (en) | Different cytotoxic t cells and methods of using them | |
AU363827S (en) | Nail care instruments | |
EP3307873A4 (fr) | Cellules hématopoïétiques et leurs méthodes d'utilisation et de préparation | |
EP3600365A4 (fr) | Méthodes de régulation de l'expression génique dans une cellule | |
IL290946A (en) | nef-containing t cells and methods for their production | |
EP3494217A4 (fr) | Cellules exprimant la lmp-1 et leurs méthodes d'utilisation | |
EP3416660A4 (fr) | Arn court en épingle à cheveux (shrna734) et son utilisation pour sélectionner positivement et éliminer des cellules génétiquement modifiées | |
EP3413865A4 (fr) | Procédés et compositions pour stimuler la synthèse du collagène dans des cellules cutanées |